PAH late-stage pipeline shows potential to expand existing therapy pathways
Over the past decade, the PAH disease space has consisted mainly of reformulations of existing PAH drugs. Credit: Joyseulay/Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more